icon
icon
Overview

Retinoblastoma is a cancer that develops in the retina, the light-sensitive layer at the back of the eye. It occurs mainly in infants and young children and may affect one or both eyes.

The cancer develops when changes involving the RB1 gene cause immature retinal cells to grow uncontrollably. Treatment aims first to protect the child's life, then preserve the eye and useful vision whenever this can be achieved safely.

At Apollo Cancer Centres, retinoblastoma care is planned by a multidisciplinary team that may include ocular oncologists, pediatric oncologists, ophthalmologists, interventional specialists, radiation oncologists, neuroradiologists, pathologists, genetic counsellors, anesthetists, and ocular rehabilitation professionals.

Risk Factors for Retinoblastoma

Most retinoblastomas develop without a known preventable cause. Factors associated with increased risk include
RB1 Gene Alteration

RB1 Gene Alteration

Changes affecting both copies of the RB1 gene within a retinal cell are central to the development of retinoblastoma
Family History

Family History

A child with a parent, sibling, or close relative who has had retinoblastoma may have an increased risk.
Heritable Retinoblastoma

Heritable Retinoblastoma

Children born with a germline RB1 variant are at risk of developing tumours in both eyes or multiple tumours within one eye.
Previous Affected Child

Previous Affected Child

Parents who have had one child with retinoblastoma may require genetic counselling before or during another pregnancy.
RB1 Mosaicism

RB1 Mosaicism

An RB1 alteration may be present in only some of the parent's or child's cells, which can complicate inheritance and risk assessment.
Heritable retinoblastoma does not always come with a known family history. A new RB1 alteration may arise in the child, and an apparently unaffected parent may occasionally have mosaicism or a variant with reduced expression.

Retinoblastoma Signs and Symptoms

Possible signs and symptoms include:

A white reflection in the pupil, called leukocoria, particularly in photographs taken with flash

One eye appearing white or yellow instead of red in photographs

Eyes that point in different directions, known as strabismus or squint

Reduced vision or difficulty following objects

Abnormal eye movements

Redness or swelling that does not resolve

Eye pain or tenderness

An enlarged or bulging eye

A change in the colour or appearance of the iris

A cloudy pupil

Bleeding inside the eye

Persistent tearing or sensitivity to light

Headache, vomiting, reduced activity, or neurological symptoms if disease has extended outside the eye

Leukocoria and squint have many possible causes, but both require prompt eye examination in a young child. Retinoblastoma can progress without causing pain, so evaluation should not be delayed while waiting for additional symptoms.

How Retinoblastoma Is Diagnosed

Diagnosis begins with a review of the child's symptoms, birth and developmental history, family history, and photographs showing an abnormal pupil reflection. Both eyes must be examined carefully because a small tumour may be present in the other eye even when only one eye appears abnormal.

• • •

Examination Under Anesthesia

Young children commonly require a detailed eye examination under anesthesia.

The ophthalmologist examines the entire retina and records:

  • Number and size of tumours

  • Location within the retina

  • Involvement of the optic disc or macula

  • Retinal detachment

  • Vitreous or subretinal tumour seeds

  • Involvement of the front of the eye

  • Potential for preserving useful vision

Retinal drawings, fundus photography, or digital imaging may be used to document the findings and monitor treatment response.

Indirect Ophthalmoscopy

Indirect ophthalmoscopy provides a wide view of the retina. It helps identify small or peripheral tumours that may not be visible during a routine eye examination.

Optical Coherence Tomography

Handheld optical coherence tomography may be used in selected children to assess the retina, macula, and small tumours in greater detail.

Ocular Ultrasound

Ultrasound can show:

  • A mass arising from the retina

  • Calcification within the tumour

  • Retinal detachment

  • Tumour size and location

  • Involvement of other structures within the eye

Calcification is common in retinoblastoma and can help distinguish it from some other childhood eye conditions.

MRI Of The Orbits And Brain

Contrast-enhanced MRI is the preferred cross-sectional imaging test.

It assesses:

  • Both eyes and optic nerves

  • Extension beyond the eyeball

  • Involvement of the tissues around the eye

  • Possible spread toward the brain

  • An associated pineal or other intracranial tumour

  • Treatment response in selected situations

MRI avoids ionising radiation, which is particularly important for children with heritable retinoblastoma.

CT Scan

CT can demonstrate calcification but is generally avoided when ultrasound and MRI can provide the required information. Limiting radiation exposure is especially important in children with a germline RB1 variant because they have an increased lifetime risk of additional cancers.

Direct Tumour Biopsy

Needle or incisional biopsy of a suspected retinoblastoma is generally avoided. Entering the eye can release tumour cells and increase the risk of cancer spreading outside the eye. Diagnosis is usually based on the characteristic eye-examination and imaging findings.

Bone Marrow And Cerebrospinal Fluid Assessment

Bone marrow examination or lumbar puncture is not routinely required for disease confined to the eye. These tests may be considered when there is evidence of optic-nerve extension, extraocular disease, neurological involvement, or metastatic spread.

Laboratory

Genetic and pathological assessment may include:

  • Histopathology: Confirms retinoblastoma after enucleation and distinguishes it from other retinal tumours.

  • Tumour differentiation: Identifies characteristic retinal structures and assesses how closely the tumour resembles developing retinal tissue.

  • Optic-nerve involvement: Determines whether tumour extends into the optic nerve and how close it comes to the surgical margin.

  • Choroidal invasion: Assesses whether cancer has entered the vascular layer beneath the retina.

  • Scleral involvement: Determines whether tumour has invaded the outer wall of the eye.

  • Anterior-segment involvement: Evaluates spread into structures at the front of the eye.

  • High-risk pathology: Deep optic-nerve, substantial choroidal, scleral, or extraocular invasion may indicate a need for additional treatment.

  • Tumour RB1 testing: May identify RB1 alterations within tumour tissue when an eye has been removed.

  • Germline RB1 testing: Determines whether the child carries an RB1 alteration in blood or another non-tumour sample.

  • Mosaicism assessment: More sensitive testing may be considered when clinical findings suggest heritable disease but routine blood testing is negative.

  • Family testing: Parents, siblings, or other relatives may be offered targeted testing when a disease-causing RB1 variant is identified.

There is no routine blood tumour marker for diagnosing or monitoring retinoblastoma. A negative blood RB1 result does not always completely exclude heritable risk, particularly when mosaicism is possible.

Staging of Retinoblastoma

Treatment planning considers both the extent within each eye and whether the cancer has spread outside the eye.

Each affected eye may be classified from Group A to Group E:

  • Group A: Small tumours located away from critical structures, without tumour seeding.

  • Group B: Larger tumours or tumours closer to the optic disc or macula, without significant seeding.

  • Group C: Localised vitreous or subretinal tumour seeding.

  • Group D: Extensive or diffuse vitreous or subretinal seeding.

  • Group E: Extensive disease with little or no potential for useful vision or features suggesting a high risk of spread outside the eye.

The classification helps estimate the likelihood of preserving the eye. It does not replace assessment of vision or extraocular extension. Staging also considers whether one or both eyes are affected, pathological risk features, and whether useful vision can be preserved.

Retinoblastoma Retinoblastoma

How Retinoblastoma Is Treated

• • •

Laser Therapy

Laser photocoagulation or transpupillary thermotherapy uses focused energy to destroy small retinal tumours or their blood supply. Several treatment sessions may be required, and the child remains under anesthesia during the procedure.

Cryotherapy

Cryotherapy applies extreme cold to destroy selected small tumours near the front of the retina. It may be repeated and can be combined with chemotherapy.

Plaque Brachytherapy

A small radioactive plaque may be temporarily attached to the outside of the eye to deliver radiation to a selected tumour. It may be used for a localised tumour that has not responded adequately to other eye-preserving treatments.

Enucleation

Enucleation removes the affected eyeball while preserving the eyelids and surrounding tissues. It may be recommended when:

  • The tumour fills most of the eye

  • Useful vision cannot be preserved

  • Painful glaucoma or other severe eye damage is present

  • There is a high risk of spread

  • Eye-preserving treatment is unlikely to be successful

  • Disease continues despite other treatment

For advanced disease in one eye, prompt enucleation may provide the safest and most effective treatment.

Removal Of Extraocular Disease

Surgery may occasionally be required for selected disease extending beyond the eye. It is combined with systemic treatment and, where appropriate, radiation therapy.

Intravenous Chemotherapy

Systemic chemotherapy can shrink intraocular tumours so they can be treated with laser or cryotherapy. This approach is often called chemoreduction. Medicines may include vincristine, etoposide, and carboplatin. Treatment selection depends on whether one or both eyes are affected, disease extent, age, and previous therapy.

Systemic chemotherapy may also be used for:

  • High-risk pathological features after enucleation

  • Extraocular disease

  • Metastatic disease

  • Trilateral retinoblastoma

  • Intra-Arterial Chemotherapy

Intra-arterial chemotherapy delivers medicine through a catheter placed into the artery supplying the eye. Medicines may include melphalan, topotecan, or carboplatin. The procedure requires a specialised interventional and pediatric anesthesia team.

Intravitreal Chemotherapy

Intravitreal chemotherapy delivers medicine directly into the vitreous cavity. It is used mainly for vitreous tumour seeds that are difficult to control with other treatments. Special injection techniques are required to minimise the risk of tumour spread outside the eye.

Treatment After Enucleation

Additional chemotherapy may be recommended if pathology identifies features associated with an increased risk of extraocular spread. Children without high-risk pathological features may not require further systemic treatment after complete enucleation.

High-Dose Chemotherapy

High-dose chemotherapy with autologous stem-cell rescue may be considered for selected metastatic or central nervous system disease. It is not required for typical intraocular retinoblastoma.

Targeted Therapy And Immunotherapy

Targeted therapies and immunotherapy do not currently have a routine established role in standard treatment for intraocular retinoblastoma. They may be studied in clinical trials or considered in exceptional advanced disease.

External Beam Radiation Therapy

External beam radiation can control retinoblastoma but is used less frequently because chemotherapy and focal treatments can often preserve the eye while limiting radiation exposure.

It may be considered for:

  • Extraocular disease

  • Central nervous system involvement

  • Selected tumours not controlled by other treatments

  • Palliative treatment of metastatic disease

Children with heritable retinoblastoma have an increased risk of additional cancers, and radiation may increase this risk further, particularly within the treated area.

Proton Therapy

Proton therapy may be considered when external radiation is necessary and reducing exposure to the brain, facial bones, opposite eye, or other developing tissues offers a meaningful advantage. It does not eliminate radiation-related risks and is not required for most children with intraocular disease.

Stereotactic Radiation Therapy

Highly focused radiation may be considered for selected intracranial or metastatic lesions. Suitability depends on the lesion's size, position, and relationship to critical structures.

Prognosis-for-Retinoblastoma
Prognosis for Retinoblastoma

The outlook is excellent when retinoblastoma is diagnosed while confined to the eye and appropriate treatment is available promptly. The likelihood of preserving the affected eye and useful vision depends on the tumour's size, location, seeding, and treatment response.

Factors influencing prognosis include:
Intraocular or extraocular disease
Optic-nerve, choroidal, scleral, or orbital invasion
Central nervous system or distant metastases
Response to eye-preserving treatment
Unilateral or bilateral disease
Germline RB1 status
Delay before diagnosis or treatment
Development of an additional cancer

Children with heritable retinoblastoma require long-term follow-up because they have an increased risk of new retinal tumours in early childhood and other cancers later in life. Radiation exposure should be limited when an effective alternative is available.

Why Choose ACC for Retinoblastoma Treatment

Multidisciplinary care involving ocular oncology, pediatric oncology, interventional treatment, radiation oncology, neuroradiology, pathology, and genetics

Detailed examination of both eyes under anesthesia

Ocular ultrasound and MRI-based assessment without unnecessary radiation exposure

Eye-preserving treatment using laser, cryotherapy, and chemotherapy where appropriate

Intra-arterial and intravitreal treatment assessment for selected children

Enucleation when required to provide safe cancer control

Specialist pathological assessment for high-risk features

Systemic treatment for high-risk, extraocular, or metastatic disease

Genetic counselling and RB1 testing for the child and family

Radiation planning, including proton therapy assessment when radiation is necessary

Ocular implants, customised prostheses, and visual rehabilitation

Long-term surveillance for recurrence, new eye tumours, visual development, and second cancers

Psychological and developmental support for children and families
Frequently Asked Questions
01 What is the most common sign of retinoblastoma?
icon icon
The most common sign is leukocoria, a white or yellow reflection in the pupil. It may be noticed directly or in photographs taken with flash.
02 Does a white pupil always mean retinoblastoma?
icon icon
No. Other eye conditions can also cause a white pupil. However, leukocoria requires prompt examination because retinoblastoma must be excluded.
03 Can retinoblastoma affect both eyes?
icon icon
Yes. Bilateral retinoblastoma usually indicates a heritable RB1 alteration. Children with tumours in both eyes require genetic testing and continued examination of both eyes.
04 Is retinoblastoma inherited?
icon icon
Some cases are heritable, including most bilateral and multifocal retinoblastomas. A child can have a heritable RB1 alteration even without a family history.
05 Why is the tumour not biopsied?
icon icon
Putting a needle or surgical instrument into the eye can allow tumour cells to escape and spread. Diagnosis is usually made through specialised eye examination and imaging.
06 Will the affected eye need to be removed?
icon icon
Not always. Small and moderately advanced tumours may be treated with laser, cryotherapy, intra-arterial chemotherapy, intravitreal chemotherapy, or systemic chemotherapy. Enucleation may be safest for an eye with extensive disease and little visual potential.
07 Can a child see normally after treatment?
icon icon
Vision depends on the tumour's size and location, particularly whether it involves the macula or optic disc. Treatment can sometimes preserve useful vision, but regular visual assessment and rehabilitation may be required.
08 What is intra-arterial chemotherapy?
icon icon
It delivers chemotherapy through a thin catheter into the artery supplying the affected eye. This concentrates treatment in the eye while limiting exposure elsewhere in the body.
09 What is intravitreal chemotherapy?
icon icon
It is chemotherapy injected directly into the vitreous cavity to treat tumour seeds floating within the eye. Special precautions are used to minimise the risk of tumour spread.
10 Will siblings need eye examinations?
icon icon
Siblings may require genetic testing or eye examination if heritable retinoblastoma is possible. The recommendations depend on the child's RB1 result and family history.
11 Can retinoblastoma return after treatment?
icon icon
Yes. A treated tumour may recur, or new tumours may develop in a genetically susceptible retina. Frequent eye examinations are required during early childhood.
12 Why is lifelong follow-up important?
icon icon
People with heritable retinoblastoma have an increased risk of other cancers later in life. Follow-up also monitors vision, eye development, treatment effects, and the ocular prosthesis when an eye has been removed.
image image
Book an Appointment
Please Enter Your Name
Please Enter Your Mobile Number
Please Enter OTP